{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:53:13Z","timestamp":1791319993166,"version":"4.3.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004388","name":"Teva Branded Pharmeceutical Products R&D Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jpsychires.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:17:11Z","timestamp":1786029431000},"page":"186-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Characterization of local tolerability of TV-46000, a long-acting subcutaneous formulation of risperidone for the treatment of schizophrenia"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2628-9442","authenticated-orcid":false,"given":"John M.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Suett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6405-3952","authenticated-orcid":false,"given":"Kelli R.","family":"Franzenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Elgart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1309-2088","authenticated-orcid":false,"given":"Antoanela","family":"Stanilescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Harary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Tohami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2026.08.002_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-244X-14-7","article-title":"A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection","volume":"14","author":"Atkins","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/PPA.S251812","article-title":"Patients' preference for long-acting injectable versus oral antipsychotics in schizophrenia: results from the patient-reported medication preference questionnaire","volume":"14","author":"Blackwood","year":"2020","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.116.055483","article-title":"Perceptions and knowledge of antipsychotics among mental health professionals and patients","volume":"41","author":"Cahling","year":"2017","journal-title":"BJPsych Bull."},{"key":"10.1016\/j.jpsychires.2026.08.002_bib4","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2026.08.002_bib5","series-title":"34th Annual Psych Congress","article-title":"Efficacy and safety of TV-46000, subcutaneous long-acting injectable risperidone, by injection site (upper arm, abdomen): post hoc analysis of the phase 3 RISE study","author":"Correll","year":"2021"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib6","series-title":"5th Annual Schizophrenia International Research Society Conference","article-title":"Safety and effectiveness of TV-46000, a long-acting subcutaneous antipsychotic (LASCA), by injection site (upper arm or abdomen): a post hoc analysis of the SHINE study","author":"Correll","year":"2023"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","article-title":"Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview","volume":"35","author":"Correll","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.2147\/NDT.S477674","article-title":"Introducing S.C.O.P.E.\u2122 (Schizophrenia clinical outcome scenarios and patient\u2013provider engagement), an interactive digital platform to educate healthcare professionals on schizophrenia care","volume":"20","author":"Correll","year":"2024","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.jpsychires.2026.08.002_bib9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib10","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24r15316","article-title":"The economic impact of cognitive impairment and negative symptoms in schizophrenia: a targeted literature review with a focus on outcomes relevant to health care decision-makers in the United States","volume":"85","author":"Correll","year":"2024","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib11","article-title":"Long-acting injectable treatments for schizophrenia: differences in attitudes and preferences among healthcare professionals and patients from the SOLARIS trial experiences study","author":"Cutler","year":"2025","journal-title":"Ann. Schizophrenia Int. Res. Soc. Conf."},{"key":"10.1016\/j.jpsychires.2026.08.002_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/2045125314542098","article-title":"A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections","volume":"4","author":"Das","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2026.08.002_bib13","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1007\/s12325-025-03274-9","article-title":"Efficacy and safety of TV-46000 and second-generation long-acting injectable antipsychotics for schizophrenia: a systematic literature review and network meta-analysis of randomized controlled trials","volume":"42","author":"Franzenburg","year":"2025","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jpsychires.2026.08.002_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1645328","article-title":"Experiences and perceptions of patients, caregivers, and healthcare professionals with long-acting injectable antipsychotics for the treatment of schizophrenia: qualitative results from the multinational ADVANCE study","volume":"16","author":"Franzenburg","year":"2025","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2026.08.002_bib15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2147\/PPA.S187120","article-title":"Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18\u201345 years old","volume":"13","author":"Gandell","year":"2019","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13696998.2017.1379412","article-title":"Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder","volume":"21","author":"Greene","year":"2018","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jpsychires.2026.08.002_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40263-023-00996-8","article-title":"A randomized, open-label, multiple-dose, parallel-arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-Month long-acting injectable in adults with schizophrenia or bipolar I disorder","volume":"37","author":"Harlin","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40263-024-01102-2","article-title":"A long-term safety and tolerability study of TV-46000 for subcutaneous use in adult and adolescent patients with schizophrenia: a phase 3, randomized, double-blinded clinical trial","volume":"38","author":"Kane","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib19","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2215-0366(23)00288-2","article-title":"Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria","volume":"10","author":"Kane","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/ppc.12267","article-title":"An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate","volume":"54","author":"Kern Sliwa","year":"2018","journal-title":"Perspect Psychiatr. Care"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/13696998.2022.2157596","article-title":"Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries","volume":"26","author":"Kotzeva","year":"2023","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jpsychires.2026.08.002_bib23","first-page":"1","article-title":"Importance of long-acting injectable antipsychotic preparation, administration, and injection site tolerability: a focus on paliperidone palmitate once-every-6-months formulation","author":"Krozer","year":"2023","journal-title":"Perspect Psychiatr. Care"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1176\/appi.ajp.20240738","article-title":"Antipsychotic drugs: a concise review of history, classification, indications, mechanism, efficacy, side effects, dosing, and clinical application","volume":"181","author":"Leucht","year":"2024","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib25","first-page":"1165","article-title":"A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use","author":"Merenlender Wagner","year":"2025","journal-title":"CNS Drugs 40"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","article-title":"Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics","volume":"176","author":"Misawa","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2026.08.002_bib27","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"P T"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12888-020-02530-2","article-title":"Attitudes of European physicians towards the use of long-acting injectable antipsychotics","volume":"20","author":"Patel","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/cpdd.1078","article-title":"Population pharmacokinetic modeling and simulation of TV-46000: a long-acting injectable formulation of risperidone","volume":"11","author":"Perlstein","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jpsychires.2026.08.002_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/npjschz.2015.39","article-title":"Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study","volume":"1","author":"Peters-Strickland","year":"2015","journal-title":"npj Schizophr."},{"key":"10.1016\/j.jpsychires.2026.08.002_bib31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/PPA.S127623","article-title":"Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic","volume":"11","author":"Pilon","year":"2017","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib32","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1007\/s12325-023-02455-8","article-title":"Patient and healthcare professional preferences for characteristics of long-acting injectable antipsychotic agents for the treatment of schizophrenia","volume":"40","author":"Robinson","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jpsychires.2026.08.002_bib33","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1176\/appi.ajp.21121189","article-title":"Effectiveness of antipsychotic use for reducing risk of work disability: results from a within-subject analysis of a Swedish national cohort of 21,551 patients with first-episode nonaffective psychosis","volume":"179","author":"Solmi","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib34","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","article-title":"Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial","volume":"72","author":"Subotnik","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12888-025-06565-1","article-title":"Clinician differences in attitudes and perceptions on the use of long-acting injectable antipsychotic agents in treating patients with schizophrenia: results from the US DECIDE survey","volume":"25","author":"Velligan","year":"2025","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgaf001","article-title":"Preferences for selecting and initiating long-acting injectable antipsychotic agents for the treatment of patients with schizophrenia: results from the US DECIDE survey","volume":"6","author":"Velligan","year":"2025","journal-title":"Schizophr Bull Open"},{"key":"10.1016\/j.jpsychires.2026.08.002_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.euroneuro.2024.03.003","article-title":"Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: systematic review and network meta-analysis","volume":"83","author":"Wang","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2026.08.002_bib39","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2147\/NDT.S309768","article-title":"Long-acting injectable antipsychotics: a systematic review of their non-systemic adverse effect profile","volume":"17","author":"Zolezzi","year":"2021","journal-title":"Neuropsychiatric Dis. Treat."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395626003924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395626003924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:27:48Z","timestamp":1791318468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395626003924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"alternative-id":["S0022395626003924"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2026.08.002","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of local tolerability of TV-46000, a long-acting subcutaneous formulation of risperidone for the treatment of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}